Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17030065 | 0.77 | HMGCR (0.42) | CYP2C19KDM4EALDH1A1HMGCRCHRM1 | |
| SCHEMBL18553616 | 0.76 | CYP2C19 (0.32) | CYP2C19KDM4EALDH1A1HMGCRCHRM1 | |
| SCHEMBL23779765 | 0.72 | ACLY (0.41) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| SCHEMBL23586671 | 0.72 | KDM4E (0.33) | CYP2C19KDM4EALDH1A1HMGCRCHRM1 | |
| SCHEMBL1560751 | 0.67 | MEN1 (0.41) | KDM4EALDH1A1 | |
| SCHEMBL20572071 | 0.66 | DGAT1 (0.36) | CYP2C19KDM4EHMGCRCHRM1TBXA2R | |
| SCHEMBL508182 | 0.65 | CYP2C19 (0.33) | CYP2C19ALDH1A1 | |
| SCHEMBL5275977 | 0.65 | MEN1 (0.35) | ALDH1A1 | |
| SCHEMBL10056337 | 0.65 | HMGCR (0.44) | CYP2C19KDM4EALDH1A1HMGCRCHRM1 | |
| SCHEMBL3498204 | 0.65 | NAALAD2 (0.33) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210138025-A1 | CATIONIC PEPTIDES WITH IMMUNOMODULATORY AND/OR ANTI-BIOFILM ACTIVITIES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210138025-A1 | CATIONIC PEPTIDES WITH IMMUNOMODULATORY AND/OR ANTI-BIOFILM ACTIVITIES | ARG1, LGALS3BP, MIF | CYP2C19 4864/4885KDM4E 3870/4885ALDH1A1 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.